Transgenic mouse core
转基因小鼠核心
基本信息
- 批准号:9884719
- 负责人:
- 金额:$ 23.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Animal Disease ModelsAnimal ModelAntibodiesAntibody-Dependent EnhancementAntibody-mediated protectionAntiviral AgentsBindingBiologicalBiological AssayBiological ModelsBiologyCell LineCellsCharacteristicsDengueDengue InfectionDimensionsDiseaseEffector CellEngineeringEpitopesEvaluationExhibitsFab domainFc domainFlavivirusFlavivirus InfectionsGenetic EngineeringGenetically Engineered MouseGenotypeHIVHepatitis B VirusHepatitis VirusesHepatocyteHumanHuman ActivitiesImmuneImmune SeraImmune responseImmune signalingImmunityImmunocompetentImmunoglobulin GIn VitroInfectionInfluenzaInterferonsLeukocytesMediatingMolecularMonoclonal AntibodiesMouse StrainsMusNaturePathogenesisPathogenicityPathway interactionsPhenotypePredispositionRag1 MouseResearch PersonnelRoleSeriesSeverity of illnessSignal PathwaySignal TransductionSurfaceSystemTransgenic MiceVaccinationViralViral PathogenesisViral PhysiologyViral hepatitisVirusVirus Diseasesanti-hepatitis Bcell typecross reactivitydefined contributionepidemiologic dataexperimental studyhumanized mouseimmunoregulationin vitro Assayin vivoin vivo Modelin vivo evaluationinnovationneutralizing antibodynovelparticlepathogenpathogenic virusreceptorreconstitutionstemvaccine responsevirus core
项目摘要
ABSTRACT – Core A, Bournazos
The ability of an IgG antibody to mediate biological effects in vivo, such as protection from viral infection, results
from its bispecific nature. The Fab region of an antibody recognizes epitopes on the viral spike and may interfere
with virus binding to target cells, while the Fc domain mediates diverse immunomodulatory activities through
specific interactions with Fcγ receptors (FcγRs) expressed by effector leukocytes. Studies on several infectious
pathogens have shown that Fc-FcγR interactions have the capacity to mediate a wide spectrum of opposing
functions – from viral opsonization and clearance of infected cells (protective) to enhanced viral infection and
disease severity (pathogenic). Understanding the precise mechanisms by which IgG antibodies mediate
protective or pathogenic functions necessitates the use of well-defined in vivo experimental systems that reflect
the unique complexity of effector leukocytes that participate in an immune response. Indeed, although in vitro
assays using cell lines or primary effector cells represent well-established approaches for characterizing the
function of IgG antibodies, such assays provide limited information on the precise molecular mechanisms that
drive human immunity during infection or upon vaccination. We will provide a Core that will maintain,
characterize, and distribute a series of genetically-engineered humanized mouse strains to the Center
investigators in support of the proposed studies on the characterization of the pathogenic activity of anti-flavivirus
antibodies that confer susceptibility to dengue disease, as well as on the evaluation of the protective antiviral
function of neutralizing antibodies against hepatitis B viruses. Through specific deletions of key immune signaling
pathways or reconstitution with human primary cells that represent the natural viral host cell type, these
engineered mouse strains support the infection and replication of flaviviruses and hepatitis viruses in vivo,
thereby facilitating the study of viral disease pathogenesis, as well as the characterization of the molecular
mechanisms that contribute to the IgG antibody activity during viral infection.
摘要-核心A,Bournazos
IgG抗体在体内介导生物学效应的能力,例如保护免受病毒感染,导致
从它的双特异性的性质。抗体的Fab区识别病毒刺突上的表位,并且可以干扰病毒刺突上的抗原表位。
与病毒结合靶细胞,而Fc结构域介导不同的免疫调节活性,
与效应白细胞表达的Fcγ受体(FcγRs)的特异性相互作用。几种传染病的研究
病原体已经表明,Fc-FcγR相互作用具有介导广谱的对抗性免疫应答的能力,
功能-从病毒调理作用和感染细胞的清除(保护性)到增强病毒感染,
疾病严重程度(致病性)。了解IgG抗体介导的精确机制
保护性或致病性功能需要使用明确的体内实验系统,
参与免疫反应的效应白细胞的独特复杂性。事实上,尽管在体外
使用细胞系或原代效应细胞的测定代表了用于表征
IgG抗体的功能,这种测定提供了有限的信息,精确的分子机制,
在感染期间或接种疫苗时驱动人体免疫力。我们将提供一个核心,
鉴定并向中心分发一系列基因工程人源化小鼠品系
研究者支持拟定的抗黄病毒致病活性表征研究
对登革热易感性的抗体,以及对保护性抗病毒药物的评价
抗B型肝炎病毒中和抗体的功能。通过特异性删除关键免疫信号
途径或用代表天然病毒宿主细胞类型的人原代细胞重建,这些
工程小鼠品系支持体内黄病毒和肝炎病毒的感染和复制,
从而促进病毒性疾病发病机理的研究,以及病毒性疾病的分子表征,
在病毒感染期间有助于IgG抗体活性的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stylianos Bournazos其他文献
Stylianos Bournazos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stylianos Bournazos', 18)}}的其他基金
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease
登革热病抗体依赖性增强机制
- 批准号:
10168774 - 财政年份:2020
- 资助金额:
$ 23.53万 - 项目类别:
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics
新型转基因小鼠模型解决了抗体治疗中突出的转化障碍
- 批准号:
10658865 - 财政年份:2020
- 资助金额:
$ 23.53万 - 项目类别:
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics
新型转基因小鼠模型解决了抗体治疗中突出的转化障碍
- 批准号:
10430052 - 财政年份:2020
- 资助金额:
$ 23.53万 - 项目类别:
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics
新型转基因小鼠模型解决了抗体治疗中突出的转化障碍
- 批准号:
10212347 - 财政年份:2020
- 资助金额:
$ 23.53万 - 项目类别:
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease
登革热病抗体依赖性增强机制
- 批准号:
10462721 - 财政年份:2018
- 资助金额:
$ 23.53万 - 项目类别:
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease
登革热病抗体依赖性增强机制
- 批准号:
10735317 - 财政年份:2018
- 资助金额:
$ 23.53万 - 项目类别:
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease
登革热病抗体依赖性增强机制
- 批准号:
10241524 - 财政年份:2018
- 资助金额:
$ 23.53万 - 项目类别:
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease
登革热病抗体依赖性增强机制
- 批准号:
9790916 - 财政年份:2018
- 资助金额:
$ 23.53万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists